URGENT: White House Unveils Sweeping Drug Price Reform

Breaking News: White House Unveils Sweeping Drug Price Reform President Trump has unveiled deals with nine pharmaceutical companies to bring their U.S. drug prices in line with what other wealthy countries pay. The agreements, reached on Friday, December 19, 2025, will allow state Medicaid programs to access lower prices from the companies involved. The nine companies that have agreed to the most-favored-nation pricing deals are Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. This brings the total number of companies participating in such deals to 14. The agreements will result in billions of dollars in savings, according to the White House. The companies will charge the U.S. government no more for new drugs than the prices paid by other well-off countries. This move is part of a broader effort to address rising healthcare costs in the United States. The Trump administration has been working to reduce the cost of prescription medications, and this announcement marks a significant step forward in that effort. The White House has also announced the launch of the TrumpRx website, which will provide information on the prices of prescription medications and the discounts available through the most-favored-nation pricing deals. This is a developing story, and we will continue to provide updates as more information becomes available.